StockNews.AI
LFMD
StockNews.AI
2 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LifeMD, Inc. - LFMD

1. Pomerantz LLP investigates potential securities fraud involving LifeMD. 2. Customer acquisition costs rose significantly impacting LifeMD's performance. 3. LifeMD's stock plummeted 44.84% following the disappointing Q2 results. 4. Analysts criticize LifeMD for losing focus during strategic transitions. 5. The investigation may lead to class action lawsuits against LifeMD.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The significant drop in stock price (44.84%) indicates a loss of investor confidence. Historical precedents show that fraud investigations often lead to further declines.

How important is it?

The investigation's implications on potential fraud could significantly affect LifeMD's market position and investor trust.

Why Short Term?

Immediate effects are visible with the stock's recent tumble, likely impacting investor sentiment quickly. However, long-term recovery depends on outcomes of the investigation.

Related Companies

TLGTHLTMDT
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether LifeMD and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On August 5, 2025, LifeMD announced its second quarter 2025 results. Among other items, the Company revealed that higher customer acquisition costs pressured its business during the June quarter. Specifically, LifeMD spent 5% to 25% more to drive new customers to its RexMD platform— a telehealth platform focusing on men’s health—in the second quarter compared to the first. In reacting to this announcement, a KeyBanc Capital Markets analyst stated that LifeMD “took its eye off the ball” in managing customer acquisition costs for RexMD amid its “enormous transition” in the quarter into the weight management space. On this news, LifeMD’s stock price fell $5.31 per share, or 44.84%, to close at $6.53 per share on August 6, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News